Overall, the median real world time on treatment for earliest olaparib monotherapy 4.6 months (95% CI 3.5 - 5.5), for patients with less than 3 lines of therapy was 5.3 months (95% CI 4.0 – 8.2), and ...

The therapy, branded as Bizengri, targets the NRG1 gene, which is associated with formation and progression of several tumors. The company did not immediately respond to a Reuters request for comment ...

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.

Pilar McLemore of Longview was involved in many nonprofits, helping the deaf and blind, the Longview Arboretum, and the ...

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

Objective Colorectal cancer is primarily treated with surgery. Major surgery and older age are risk factors associated with postoperative decline in cognitive function. In clinical research, a wide ...

The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.

Rhode Island ranked second for its lung cancer survival rate, with more than 35% living five years post diagnosis. The state ...

In one magical moment on Wednesday, Santa Claus worked with Princess Elsa of "Frozen" films to deliver a glorious wish to ...

Merus said the Food and Drug Administration approved Bizengri, the first treatment for adults diagnosed with pancreatic adenocarcinoma or non-small cell lung cancer that are advanced unresectable or ...

The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.

The 66th American Society of Hematology Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, ...